Spectral Diagnostics
BioMS Medical and Spectral Diagnostics Inc. (TSX:SDI) announced a strategic collaboration on December 17, 2009. Spectral is a leader in the battle against sepsis.
- Under the terms of the agreement BioMS invested $12 million to acquire 30,000,000 Units of Spectral. Upon closing the financing BioMS will own 30,000,000 Common Shares and 15,000,000 Warrants
- The investment represents approximately 39.6% of Spectral’s issued and outstanding Common Shares
- Includes a three year $3 million service whereby BioMS will provide clinical, regulatory and capital market consulting services to Spectral
- BioMS will be entitled to nominate up to two directors to the Spectral board
- On March 3, 2010 BioMS Reported that Spectral Received FDA approval to Initiate the Pivotal Trial and Closed the Financing for $19.5 Million. To learn more, please click here.
To learn more about the BioMS and Spectral collaboration please click here.
To learn more about sepsis, please click here.